Compare DRMA & VERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRMA | VERO |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.2M |
| IPO Year | 2021 | N/A |
| Metric | DRMA | VERO |
|---|---|---|
| Price | $2.27 | $1.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 1.8M | ★ 17.5M |
| Earning Date | 03-16-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $58,876,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.58 | $1.16 |
| 52 Week High | $23.70 | $14.50 |
| Indicator | DRMA | VERO |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 45.79 |
| Support Level | $2.33 | $1.16 |
| Resistance Level | $3.01 | $1.86 |
| Average True Range (ATR) | 0.51 | 0.78 |
| MACD | 0.06 | -0.17 |
| Stochastic Oscillator | 17.59 | 1.06 |
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.